GenSpera (OTCQB:GNSZ) Names JPA Health Communications as Its Agency of Record
SAN ANTONIO - January 6, 2015 (Investorideas.com Biotech Newswire) GenSpera, Inc. (OTCQB:GNSZ), a San Antonio based biotech company that develops innovative prodrug therapeutics for the treatment of cancer, announced today that it has named JPA Health Communications as its public relations agency of record.
By leveraging its deep expertise in oncology, JPA will handle GenSpera's external communications for the company and its investigational agent mipsagargin, currently in Phase II clinical development for patients with liver cancer (hepatocellular carcinoma) and brain cancer (glioblastoma).
"This is an exciting time for GenSpera and we are pleased to enlist an agency that understands the complexity of oncology drug development and the important responsibility of engaging the patient community," said Craig Dionne, Ph.D., chief executive officer of GenSpera.
JPA Health Communications is an award-winning communications firm that designs and implements strategic health campaigns for pharmaceutical, non-profit and government clients. As leaders in influencer relations, JPA uses a targeted approach to reach the stakeholders who drive change and deliver measurable results. The agency is headquartered in Washington, D.C., with offices in London and the biotech center of Cambridge, Mass.
"We are honored to be selected to partner with GenSpera at this key time in the company's development," said Carrie Jones, principal and managing director at JPA Health Communications. "GenSpera is an excellent cultural fit with our firm and they share our passion for science and brand communications."
Read this release in full at http://www.investorideas.com/CO/GNSZ/news/2015/01061.asp
GenSpera's technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that provides for the targeted release of drug candidates within a tumor. GenSpera's lead drug candidate, mipsagargin, is activated by the enzyme PSMA, which is found at high levels in the vasculature of liver and glioblastoma cancers, and in the vasculature of almost all other solid tumors. Mipsagargin is therefore expected to have potential efficacy in a wide variety of tumor types. The U.S. Food and Drug Administration (FDA) granted Orphan Drug designation in 2013 for the evaluation of mipsagargin in patients with hepatocellular carcinoma (liver cancer). Mipsagargin Phase II clinical trials are underway in both hepatocellular carcinoma and glioblastoma patients (brain cancer). For more information, please visit the company's website: www.genspera.com or follow us on Twitter @GenSperaNews. Company presentations are available at: http://www.genspera.com/
Cautionary Statement Regarding Forward Looking Information
This news release may contain forward-looking statements. Investors are cautioned that statements in this press release regarding potential applications of GenSpera's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties will be detailed from time to time in GenSpera's periodic reports filed with the Securities and Exchange Commission.
Disclaimer/Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: GNSZ is a previous showcase company which expired on December 18, 2014. Investorideas is long 144 shares
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
Become an Investorideas.com Member and access our 14 online stock directories 24/7 –biotech, mining stocks, oil and gas stocks and more... http://www.investorideas.com/membership/